Edesa Biotech Issues Letter to Shareholders
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020.
Dear Fellow Shareholders,
It would be difficult to begin any year-end review without acknowledging the impact that the global health crisis has had on our communities and families, our economy, and on our operations. 2020 has been anything but an ordinary year.
While Edesa s first full year as a public company brought unexpected challenges, it also brought opportunities to demonstrate the flexibility and breadth of our clinical development strategy. During the past twelve months, despite lock-downs and other pandemic related disruptions, we continued to deliver on corporate and clinical milestones, expanded our pipeline, and set our sights on new, ambitious goals. While much work remains, I am pleased to re
Q BioMed Updates Shareholders at Year End
Company Expects Several Milestones as Momentum Builds for 2021
News provided by
Share this article
Dear Fellow Shareholders,
As 2020 draws to a close, we join the rest of the world in looking forward to a new year with new beginnings and hope for a quick return to whatever the new normal will be. Leaving behind the constant threat of lockdowns and the interruption the COVID-19 pandemic has had on our lives will be a welcome change.
With that in mind we acknowledge that 2020 was not the year we promised and feel even more committed to achieving our stated goals. We learned a great deal about Q BioMed s place in the fragile world in which we live and operate. With the 20/20 view of hindsight, we are excited about the coming year.
TMCnet News
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem s ARDS Associated With COVID-19 Program to Mexico
[December 29, 2020]
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem s ARDS Associated With COVID-19 Program to Mexico
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration (FDA) cleared
By Reuters Staff
11 Min Read
With the number of coronavirus deaths in the United States surpassing 300,000, social media posts claim, “A virus DID NOT kill 300,000 Americans. Old age did. Pharmaceuticals did. Processed foods did. Pesticides did. Hospitals & Ventilators did. Lack of proper nutrition, sunlight & exercise did.” Some of these things can contribute to pre-existing conditions that make serious illness from COVID-19 more likely. These deaths, however, were triggered by the novel coronavirus.
Reuters Fact Check. REUTERS
Social media posts making this claim can be found here , here and here .
As stated here on the Centers for Disease Control and Prevention’s (CDC) “Provisional Death Counts for Coronavirus Disease 2019 (COVID-19)” page, COVID-19 was the only cause mentioned for 6% of recorded U.S. coronavirus deaths. In other words, more than 16,500 of the more than 276,061 processed death certificates included in the CDC’s provisional death count had only C
Zydus Cadila—the Rising Star Of Vaccines forbesindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbesindia.com Daily Mail and Mail on Sunday newspapers.